Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
McKinsey
Moodys
McKesson
Dow

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Cenicriviroc

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Cenicriviroc?

Cenicriviroc is an investigational drug.

There have been 12 clinical trials for Cenicriviroc. The most recent clinical trial was a Phase 2 trial, which was initiated on April 20th 2017.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Cirrhosis. The leading clinical trial sponsors are Tobira Therapeutics, Inc., Allergan, and University of Hawaii.

There are eight US patents protecting this investigational drug and seventy international patents.

Recent Clinical Trials for Cenicriviroc
TitleSponsorPhase
Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (TANDEM)AllerganPhase 2
Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (TANDEM)Novartis PharmaceuticalsPhase 2
AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASHTobira Therapeutics, Inc.Phase 3

See all Cenicriviroc clinical trials

Clinical Trial Summary for Cenicriviroc

Top disease conditions for Cenicriviroc
Top clinical trial sponsors for Cenicriviroc

See all Cenicriviroc clinical trials

US Patents for Cenicriviroc

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cenicriviroc   Start Trial Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate Tobira Therapeutics, Inc. (South San Francisco, CA)   Start Trial
Cenicriviroc   Start Trial Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer Universite Paul Sabatier (Toulouse III) (Toulouse, FR) Centre National de la Recherche Scientifique (Paris, FR) Centre Hospitalier Universitaire de Toulouse (Toulouse, FR) Institut National de la Sante et de la Recherche Medicale (Paris, FR)   Start Trial
Cenicriviroc   Start Trial Purified cenicriviroc and purified intermediates for making cenicriviroc Tobira Therapeutics, Inc. (Parsipanny, NJ)   Start Trial
Cenicriviroc   Start Trial Bicyclic compound, production and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Cenicriviroc   Start Trial Bicyclic compound, production and use thereof Tobira Therapeutics, Inc. (Princeton, NJ)   Start Trial
Cenicriviroc   Start Trial Bicyclic compound, production and use thereof Tobira Therapeutics, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cenicriviroc

Drugname Country Document Number Estimated Expiration Related US Patent
Cenicriviroc Australia 2017321594 2036-08-31   Start Trial
Cenicriviroc Brazil 112019003987 2036-08-31   Start Trial
Cenicriviroc Canada 3034606 2036-08-31   Start Trial
Cenicriviroc China 110167550 2036-08-31   Start Trial
Cenicriviroc European Patent Office 3506896 2036-08-31   Start Trial
Cenicriviroc South Korea 20190057066 2036-08-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Moodys
Mallinckrodt
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.